~~<i id='976E9D72ED'><strike id='976E9D72ED'><tt id='976E9D72ED'><pre id='976E9D72ED'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

explore

author：hotspot 2025-09-30 08:53:13 - browse：7

Adam's take main illustration — Molly Ferguson/STAT

I was wrong about Geron.

For years, I’ve believed — and declared publicly — that Geron’s effort to develop a blood cancer drug called imetelstat would end in disappointment. The drug was never getting approved, I said.

On Thursday, a group of outside experts convened by the Food and Drug Administration voted 12-2 in imetelstat’s favor, concluding the drug’s benefits outweighed its risks for the treatment of patients with myelodysplastic syndrome. The strong endorsement makes an FDA approval highly likely. The decision is expected on or before June 16.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： UpToDate has a racism problem: Dr. Stanley Goldfarb

explore

hotspot

focus

Wikipedia

hotspot

EricTokatisco-presidentofinvestmentbankingatCenterviewPartners.CourtesyCenterviewPartnersSANFRANCISC

WSS

Security flaws in third

Fauci's latest grilling in Congress: 9 hours, behind closed doors

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Nonprofit, backed by Microsoft, to certify AI tools in health care

hotspot

explore

explore

Continuity nursing helped my family in our darkest PICU moments

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Alkermes shareholders re

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

As demand for Covid shots wanes, Moderna seeks its next success

Does Paxlovid work in people vaccinated against Covid

How one medical school became remarkably diverse

Canadians with cystic fibrosis outlive Americans by a decade

Walensky prepares to leave CDC — and Congress — behind

FDA early review: GLP

hotspot

Nonprofit, backed by Microsoft, to certify AI tools in health care

What affirmative action's end means to a medical student

A preacher's new calling: Diversifying neuroscience research

Boston Scientific acquires urology company Axonics for $3.7 billion

Vertex cell therapy lets patients with type 1 diabetes stop insulin

FDA early review: GLP

focus

Wikipedia

Wikipedia

hotspot